As of Aug 25
| +0.16 / +1.24%|
The 6 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 17.00, with a high estimate of 22.00 and a low estimate of 13.00. The median estimate represents a +30.47% increase from the last price of 13.03.
The current consensus among 7 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.